Trevi Therapeutics (TRVI) News Today $4.05 -0.10 (-2.41%) (As of 12/20/2024 05:45 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Trevi Therapeutics Announces Pricing of $50 Million Underwritten OfferingDecember 16, 2024 | prnewswire.comTrevi Therapeutics' (TRVI) Buy Rating Reaffirmed at Needham & Company LLCDecember 15, 2024 | americanbankingnews.comOptimistic Buy Rating for Trevi Therapeutics Amid Promising Phase 2b Trial ResultsDecember 13, 2024 | markets.businessinsider.comRetail Chatter For Trevi Therapeutics Soars After Enrollment Target For Chronic Cough Study Hits 75%December 13, 2024 | msn.comPositive Outlook on Trevi Therapeutics: Stable Phase 2b Trial Results Boost Confidence in Haduvio and Market PotentialDecember 12, 2024 | markets.businessinsider.comTrevi Therapeutics Shares Hit 52-Week High After Positive Trial AnalysisDecember 12, 2024 | marketwatch.comTrevi stock rockets on Haduvio study updateDecember 12, 2024 | seekingalpha.comTrevi Reports Positive Outcome From Sample Size Re-estimation For Phase 2b CORAL Study; Stock UpDecember 12, 2024 | markets.businessinsider.comTrevi Therapeutics Announces Positive Outcome from Sample Size Re-estimation Resulting in No Change to the Current Sample Size for the Phase 2b CORAL Trial in Idiopathic Pulmonary Fibrosis Patients with Chronic CoughDecember 12, 2024 | prnewswire.comHC Wainwright Predicts Lower Earnings for Trevi TherapeuticsTrevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) - Equities researchers at HC Wainwright reduced their FY2024 earnings per share (EPS) estimates for Trevi Therapeutics in a research note issued on Wednesday, December 4th. HC Wainwright analyst O. Livnat now anticipates that the company will pDecember 9, 2024 | marketbeat.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Given Consensus Recommendation of "Buy" by BrokeragesShares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) have been assigned an average rating of "Buy" from the ten research firms that are currently covering the company, Marketbeat reports. Eight investment analysts have rated the stock with a buy rating and two have issued a strong buDecember 8, 2024 | marketbeat.comBuy Rating Affirmed for Trevi Therapeutics: Haduvio’s Market Potential Outweighs Scheduling ConcernsDecember 6, 2024 | markets.businessinsider.comBuy Rating for Trevi Therapeutics: Strong HAP Study Results and Potential Catalysts Bolster ConfidenceDecember 6, 2024 | markets.businessinsider.comJonesTrading Remains a Buy on Trevi Therapeutics (TRVI)December 5, 2024 | markets.businessinsider.comTrevi Therapeutics: Undervalued Stock with High Potential in Chronic Cough Market Despite Low Abuse ConcernsDecember 5, 2024 | markets.businessinsider.comOppenheimer Remains a Buy on Trevi Therapeutics (TRVI)December 5, 2024 | markets.businessinsider.comTrevi Therapeutics price target raised to $9 from $8 at JonesResearchDecember 5, 2024 | markets.businessinsider.comCompanies Like Trevi Therapeutics (NASDAQ:TRVI) Are In A Position To Invest In GrowthDecember 4, 2024 | finance.yahoo.comTrevi Therapeutics Reports Positive Results for Human-Abuse Potential of Oral NalbuphineDecember 3, 2024 | marketwatch.comTrevi stock tumbles 23% amid Haduvio study resultsDecember 3, 2024 | msn.comTrevi Therapeutics Announces Positive Topline Results from Human Abuse Potential Study of Oral NalbuphineDecember 3, 2024 | prnewswire.comTrevi Therapeutics to Participate in Piper Sandler 36th Annual Healthcare ConferenceNovember 21, 2024 | prnewswire.comPromising Prospects for Trevi Therapeutics’ Haduvio in Addressing Unmet Needs in Refractory Chronic CoughNovember 18, 2024 | markets.businessinsider.comRome’s Trevi Fountain unveils elevated walkway for tourists to get closer look during cleaningNovember 14, 2024 | msn.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Given Consensus Rating of "Buy" by AnalystsShares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) have been assigned a consensus recommendation of "Buy" from the nine research firms that are presently covering the stock, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy rating and two hNovember 13, 2024 | marketbeat.comLeerink Partnrs Has Negative Outlook of TRVI FY2024 EarningsTrevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) - Equities researchers at Leerink Partnrs lowered their FY2024 earnings estimates for shares of Trevi Therapeutics in a report issued on Wednesday, November 6th. Leerink Partnrs analyst F. Khurshid now anticipates that the company will post earNovember 11, 2024 | marketbeat.comRome's Trevi Fountain gets temporary catwalk as famous landmark undergoes a cleaningNovember 10, 2024 | msn.comTourists in Rome now have a walkway to visit the Trevi Fountain but can’t toss coinsNovember 10, 2024 | apnews.comTrevi Therapeutics: Buy Rating Driven by Promising Haduvio Potential and Key Study DevelopmentsNovember 9, 2024 | markets.businessinsider.comTrevi Therapeutics: Promising Pipeline and Strategic Developments Support Buy RatingNovember 9, 2024 | markets.businessinsider.comTrevi Therapeutics (NASDAQ:TRVI) Given Buy Rating at Needham & Company LLCNeedham & Company LLC reaffirmed a "buy" rating and set a $8.00 price objective on shares of Trevi Therapeutics in a report on Friday.November 8, 2024 | marketbeat.comTrevi Therapeutics: Buy Rating Affirmed Amid Promising Haduvio Prospects and Upcoming Data MilestonesNovember 8, 2024 | markets.businessinsider.comStifel Nicolaus Keeps Their Buy Rating on Trevi Therapeutics (TRVI)November 7, 2024 | markets.businessinsider.comTrevi Therapeutics Reports Q3 2024 Progress and FinancialsNovember 7, 2024 | markets.businessinsider.comTrevi Therapeutics Inc (TRVI) Q3 2024 Earnings Call Highlights: Navigating Increased Losses and ...November 7, 2024 | finance.yahoo.comTrevi Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdatesNovember 6, 2024 | prnewswire.comRosalind Advisors Inc. Has $2.51 Million Stake in Trevi Therapeutics, Inc. (NASDAQ:TRVI)Rosalind Advisors Inc. reduced its position in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 46.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 750,000 sharesNovember 6, 2024 | marketbeat.comThe Trevi Fountain Now Features a Kiddie PoolNovember 4, 2024 | msn.comTrevi fountain maintenance: Tradition preserved with coin poolNovember 3, 2024 | msn.comPool at Rome’s Trevi Fountain for coin tossing as the monument is repairedNovember 2, 2024 | apnews.comTourists toss coins over makeshift pool as Rome’s Trevi Fountain undergoes maintenanceNovember 1, 2024 | msn.comTrevi Therapeutics (TRVI) Set to Announce Quarterly Earnings on WednesdayTrevi Therapeutics (NASDAQ:TRVI) will be releasing earnings after the market closes on Wednesday, November 6, Zacks reports.October 31, 2024 | marketbeat.comTrevi Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on November 6, 2024October 30, 2024 | prnewswire.comInside A Clothing Store In Rome Are The Best Hidden Views Of The Trevi FountainOctober 25, 2024 | msn.comTrevi Therapeutics Positioned for Growth with Advancements in Chronic Cough Treatment and Undervalued Market PotentialOctober 22, 2024 | markets.businessinsider.comTrevi Therapeutics (NASDAQ:TRVI) Given "Buy" Rating at HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $6.00 price target on shares of Trevi Therapeutics in a research note on Tuesday.October 22, 2024 | marketbeat.comStifel says Trevi’s RIVER enrollment completion puts data release in Q1 2025October 22, 2024 | markets.businessinsider.comTrevi Therapeutics completes enrollment for Phase 2a RIVER trialOctober 22, 2024 | markets.businessinsider.comTrevi Therapeutics Completes Enrollment for Phase 2a RIVER Trial in Refractory Chronic CoughOctober 21, 2024 | prnewswire.comGloria Trevi & Maria Becerra Dazzle With Daring ‘Borracha’ Performance at 2024 Latin Music AwardsOctober 21, 2024 | msn.com Get Trevi Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TRVI and its competitors with MarketBeat's FREE daily newsletter. Email Address How Low-Cost Stocks Generate Monthly Income (Ad)Are you ready to transform your investment strategy and generate a steady monthly income? We’re excited to offer you our exclusive report, "Options Trading Strategy: 2 (Surprisingly) Low-Cost Stocks Primed for Generating Monthly Income," FREE! 👉 Yes, I Want the Free Report! 👈 TRVI Media Mentions By Week TRVI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TRVI News Sentiment▼0.000.60▲Average Medical News Sentiment TRVI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TRVI Articles This Week▼23▲TRVI Articles Average Week Get Trevi Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TRVI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ARVN News DAWN News ARDX News SYRE News CALT News SPRY News ANIP News SNDX News RCKT News BCYC News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TRVI) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Trevi Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Trevi Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TRVI Stock Alerts